New First-line Therapy Now Available For Treatment Of Advanced Hormone Receptor Posit
 

TykerbTM (lapatinib ditosylate) has received Health Canada approval for use in combination with letrozole (an aromatase inhibitor) for the treatment of post-menopausal women with hormone receptor-positive (HR+) metastatic breast cancer, whose tumours overexpress the HER2 (ErbB2) receptor, and who are suitable for endocrine therapy...

More...